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Kohlhapp et al. report that non-oncogenic
infections shunt anti-cancer CD8+ T cells
from the tumor to the site of infection and
accelerate cancer growth and host death.
PD-1 blockade immunotherapy reverses
this effect. These findings may explain
increased cancer-specific death in
patients with cancer-unrelated acute and
chronic infections.
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In light of increased cancer prevalence and cancer-
specific deaths in patients with infections, we inves-
tigated whether infections alter anti-tumor immune
responses. We report that acute influenza infection
of the lung promotes distal melanoma growth in
the dermis and leads to accelerated cancer-specific
host death. Furthermore, we show that during influ-
enza infection, anti-melanoma CD8+ T cells are
shunted from the tumor to the infection site, where
they express high levels of the inhibitory receptor
programmed cell death protein 1 (PD-1). Immuno-
therapy to block PD-1 reverses this loss of anti-tumor
CD8+ T cells from the tumor and decreases infection-
induced tumor growth. Our findings show that
acute non-oncogenic infection can promote cancer
growth, raising concerns regarding acute viral illness
sequelae. They also suggest an unexpected role for
PD-1 blockade in cancer immunotherapy and pro-
vide insight into the immune response when faced
with concomitant challenges.
INTRODUCTION
Our current understanding of immunity relies principally on
studies in which a single type of challenge or re-challenge isCell
This is an open access article under the CC BY-Nmade to the immune system. Such work has been instrumental
in deconstructing complicated immune cell functions and intri-
cate molecular signaling networks. However, the immune sys-
tem is often tasked with responding to multiple concomitant
challenges, and how one type of challenge dictates the immune
response to another is not well understood.
The majority of the work thus far on concomitant challenges
has been done in the context of pathogenic co-infections, and
findings in this field are discordant (Kenney et al., 2015; Mueller
et al., 2007; Osborne et al., 2014; Stelekati et al., 2014). Further,
although infections and cancers are two of the most common
human maladies and cancer patients are at increased risk of in-
fections, very little information is available regarding the conse-
quences of concomitant non-oncogenic infection and cancer;
thus, this subject is a matter of ongoing debate (Cooksley
et al., 2005; Kohler et al., 1990; Wong et al., 2010). Case studies
performed in the late 19th century report cancer regression in the
context of infection-like reactions (e.g., in response to Coley’s
toxin), and recent work proposes that anti-tumor T cell popula-
tions can be expanded as a by-product of infection (Coley,
1891; Garrett, 2015; Iheagwara et al., 2014). However, emerging
epidemiological studies report an increased prevalence of can-
cers and increased cancer-specific death in patients with infec-
tion (Attie^ et al., 2014; Cox et al., 2010; Crum-Cianflone et al.,
2009; Huang et al., 2013; Su et al., 2011; Swaminathan et al.,
2015).
Therefore, toward advancing the scientific understanding
of immunity in the context of multiple concomitant chal-
lenges, we investigated the effect of acute, non-oncogenic,Reports 17, 957–965, October 18, 2016 ª 2016 The Author(s). 957
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
non-immune-destructive infection in one tissue on anti-cancer
immune responses in a distal tissue. Surprisingly, we uncovered
a potentially common mechanism of immune disruption in can-
cer-bearing hosts, namely the shunting of anti-tumor CD8+
T cells from the tumor microenvironment to the site of infection
by acute non-oncogenic pathogens, an unexpected mechanism
of programmed cell death protein 1 (PD-1) blockade in the treat-
ment of cancer, and an important perspective to our basic
understanding of the immune response in the context of
concomitant challenges.
RESULTS AND DISCUSSION
Acute Influenza Infection Leads to Accelerated Cancer-
Specific Host Death
To determine the impact of viral infection on cancer-specific
mortality, we inoculated B6 mice with influenza 3 days before
distal tumor challenge with B16 melanoma (Figure 1A). Influenza
infection significantly accelerated cancer-specific host death
(p < 0.001; Figure 1A). Furthermore, influenza infection as
many as 30 days before tumor challenge likewise accelerated
host death, albeit to a smaller degree compared with infection
3 days before tumor challenge (Figure 1B). Cancer-specific
mortality was similar in mice infected and not infected with influ-
enza 60 days before tumor challenge (Figure 1C). These data
demonstrate that acute influenza infection leads to accelerated
cancer-specific host death.
Influenza Infection Accelerates the Death of Hosts with
Established Tumors and Leads to the Emergence of
Otherwise Controlled Tumors
To determine whether influenza similarly affects established tu-
mor growth, we challenged mice with B16 melanoma and then
infected them 3 or 7 days later with influenza. Here, influenza
infection of hosts with established tumors likewise accelerated
cancer-specific host death (Figure 1D).
To determinewhether infection could lead to the emergence of
cancer that is otherwise controlled by the immune system, we
challenged mice with suboptimal cell numbers of B16 (12,000
and 1,200) at which the percentage of tumor-free mice is
increased (to 60% and 100%, respectively) compared with our
optimal challenge with 120,000 cells (Figure 1E). Here, influenza
infection significantly decreased the percentage of tumor-free
mice at both 12,000 and 1,200 B16 cell challenges to 0% (p <
0.05 and p < 0.01, respectively; Figure 1E). These data show
that concomitant influenza accelerates the death of hosts with
established tumors and leads to the emergence of otherwise
controlled tumors.
Infection-Accelerated Tumor Growth and Host Death
Occur in the Context of Various Pathogens and Cancers
To determine whether these findings are more broadly appli-
cable, we challenged mice with a series of pathogens, adminis-
tered through different sites of infection and via varying routes of
delivery. Acute lymphocytic choriomeningitis virus (LCMV; Arm-
strong strain) infection, which infects the spleen, liver, and
kidneys and is administered via intraperitoneal (i.p.) injection
(Ahmed et al., 1984), results in significantly accelerated host958 Cell Reports 17, 957–965, October 18, 2016death (p < 0.001; Figure 2A). Furthermore, this phenomenon is
not restricted to viruses because concomitant bacterial infection
with Staphylococcus aureus also hastened tumor growth (p <
0.05; Figure 2B). These findings are not restricted to transplant-
able tumormodels, because in a genetically drivenmousemodel
of melanoma (utilizing heterozygous Braf/PTENmice), increased
melanoma was observed in mice infected with influenza and
complete penetrance was observed when tamoxifen and influ-
enza were combined (Figure 2C). To assess whether the results
observed are applicable to a cancer of another type, in a different
tissue, and in a different mouse strain, we determined the effects
of influenza infection on 4T1 breast cancer in the mammary
fat pad of Balb/c mice. Here, influenza infection significantly
increased tumor growth (p < 0.05) (Figure 2D). Collectively, these
data show that infection-accelerated tumor growth and host
death occur in the following various contexts: (1) tumor types,
(2) sites of tumor challenge, (3) mouse strains, (4) infectious
agents, (5) sites of infection, and (6) models of tumor induction.
Anti-tumor CD8+ T Cells Are Shunted to the Lung during
Influenza Infection
CD8+ T cells are important mediators of immunity, tasked with
clearing both viral infections and tumors. Therefore, to elucidate
the mechanism by which influenza infection promotes tumor
growth and reduces survival, we determined the proportion of
anti-tumor CD8+ T cells within the tumor and at the infection
site. To track anti-tumor CD8+ T cells, we adoptively trans-
ferred Thy1.1+ Pmel CD8+ T cells specific against melanoma
gp10025–33 into Thy1.1
 B6 mice (Figure 3A). Surprisingly, in
mice infectedwith influenza, Pmel CD8+ T cells were significantly
reduced on day 15 in the tumor compared with uninfected hosts
(p < 0.01) and found at high levels at the site of infection (p <
0.001; Figures 3B and 3C). Similar findings were observed in
terms of Pmel CD8+ T cell numbers in the tumor and lungs (Fig-
ure 3D), but were not observed in tissues unrelated to the tumor
challenge or infection (Figure 3E).
To determine whether anti-tumor CD8+ T cells could traffic
from the tumor to the influenza-infected lungs, we transplanted
tumors from uninfected B16 melanoma-bearing B6 mice (that
previously received an adoptive transfer of Pmel CD8+ T cells)
to naive B6 mice that were subsequently influenza-infected or
left uninfected (Figure 3F). Influenza infection resulted in the sig-
nificant accumulation of tumor-specific (Pmel) CD8+ T cells from
the transplanted tumors in the influenza-infected lungs (p < 0.01)
but not spleen (Figure 3G). This finding shows that anti-tumor
CD8+ T cells are shunted by a distal infection from the tumor to
the site of infection.
Disruption of Anti-tumor Responses Is Not Due to
Tumor-Induced Immune Suppression of Viral Clearance
or the Inability of the Immune System to Respond to
Concomitant Challenges
To assess whether the observed disruption of anti-tumor re-
sponses leading to accelerated cancer-specific death is due to
tumor-induced immune suppression, we inoculated two groups
of B6 mice with influenza and challenged one of those
groups with distal B16 melanoma. Notably, tumor challenge
did not suppress the immune clearance of influenza (Figure S1A),
Figure 1. Influenza Infection Results in Accelerated Melanoma-Specific Host Death
(A) Experimental design (top). Survival of B6 mice infected on day 3 with influenza and challenged with B16 melanoma on day 0 via intradermal (i.d.) injection
(bottom).
(B) Experimental design (top). Survival of B6 mice infected on days 3, 15, or 30 with influenza and challenged with B16 melanoma on day 0 (bottom).
(C) Survival of B6 mice infected on day 60 with influenza and challenged with B16 melanoma on day 0.
(D) Experimental design (top). Survival of B6 mice infected on days +3 or +7 with influenza and challenged with B16 melanoma on day 0 (bottom).
(E) Experimental design (top). Percentage of B6 mice remaining tumor-free after infection on day 3 with influenza and challenge with B16 melanoma (120,000,
12,000, or 1,200 cells) on day 0 (bottom).
All experiments were performed with 7–10 mice per group with at least two independent repeat experiments. Survival was defined by tumor size < 100 mm2. *p <
0.05; **p < 0.01; ***p < 0.001. ns, not significant.
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Figure 2. Pathogenic Infections Accelerate Tumor Growth in the Context of Various Cancers
(A) Experimental design (top). Survival of B6 mice infected with LCMV (Armstrong strain) on day 3 and challenged with B16 melanoma on day 0 via intradermal
(i.d.) injection (bottom). Survival was defined by tumor size < 100 mm2.
(B) Experimental design (top) and wound and infection diagram (bottom left). Tumor growth in B6 mice challenged with B16 melanoma on day 0, wounded on
day +3, and infected at day +3 with Staphylococcus aureus via intra-wound (i.w.) injection (bottom right).
(C) Experimental design (top). Tumor incidence in Braf/PTEN mice infected at 8 weeks of age with influenza and/or treated with 4HT on day 0. Representative
images and number and percentages of mice with one or more observed tumors on day 60 from two combined experiments (bottom). Red arrows and circle
indicate areas of melanoma growth.
(D) Experimental design (top). Balb/c mice were infected on day 3 with influenza and challenged with 4T1-Luciferase (4T1-Luc) murine breast cancer cells on
day 0 via intra-mammary fat pad (i.mfp.) injection. Tumor growth was measured using the live imaging IVIS system (bottom). Results are depicted with repre-
sentative luminescence images (bottom left) and cumulative bar graphs (bottom right). Dashed line depicts background luminescence.
All experiments were performedwith 5–10mice per groupwith at least two independent repeat experiments. *p < 0.05; ***p < 0.001. Error bars represent the SEM.demonstrating that cancer in these hosts does not significantly
suppress the anti-viral response.
To determine whether accelerated cancer-specific death is
due to a general inability of the immune system to respond to
concomitant challenges, we infected B6 mice on day 3 with
influenza and/or with vaccinia virus (VACV) on day 0. Importantly,
influenza infection did not alter the natural clearance of VACV
(Figure S1B) or the proportion of VACV-tetramer+ CD8+ T cells
at the site of influenza infection (Figures S1C and S1D), suggest-
ing that influenza infection does not in general prevent concom-
itant disease clearance, but does accelerate tumor growth in our
studies.960 Cell Reports 17, 957–965, October 18, 2016Therapeutic Blockade of PD-1 Results in Reversal of
Infection-Mediated Anti-tumor Response Disruption
Based on the extended period of time necessary after infection
clearance for anti-tumor immune responses to be recovered
(Figures 1B and 1C), we hypothesized that infection leads to
the dysfunction of anti-tumor CD8+ T cells shunted to the site
of infection. Because exhaustion is a hallmark of dysfunctional
anti-tumor CD8+ T cells (Ahmadzadeh et al., 2009; Sakuishi
et al., 2010; Wherry et al., 2007), we determined the expression
of activation and exhaustion receptor, PD-1, on tumor-specific
CD8+ T cells. Although PD-1 expression was observed on
anti-tumor Pmel CD8+ T cells in the tumor (10%–20%; A.Z.,
Figure 3. Melanoma-Specific CD8+ T Cells Are Shunted from the Tumor to the Site of Infection
(A) Experimental design for studies in which B6 mice received adoptive cell transfer (ACT) of Pmel cells on day 5, were infected with influenza on day 3, and
were challenged with B16 melanoma on day 0.
(B) Tumors from experiment described in (A) were resected at day 15 and analyzed via flow cytometry. Results depicted by representative flow plots show% of
Pmel CD8+ T cells among all CD8+ T cells. Axes on all plots are log scale.
(C) Cumulative bar graphs showing percentage of Pmel CD8+ T cells determined from the experiment described in (A).
(D) Cumulative bar graphs showing number of Pmel CD8+ T cells determined from the experiment described in (A).
(E) Cumulative bar graphs showing percentage of Pmel CD8+ T cells determined from the experiment described in (A).
(F) Experimental design for studies in which B6 mice (Thy1.1; donor mice) received ACT of Pmel cells (Thy1.1+) on day 5 and were challenged with B16
melanoma on day 0. On day 12, each tumor (36mm2) was resected and transplanted into the intradermal space of the right flank of two naive B6mice (recipient
mice). On day 17, one of two naive B6 tumor-recipient mice from each pair was infected with influenza.
(G) Tumor, lungs, and spleen frommice in the experiment described in (F) were resected on day 25, and the presence of Pmel CD8+ T cells was determined by flow
cytometry.
All experiments were performed with 5–10mice per group with at least two independent repeat experiments. **p < 0.01; ***p < 0.001. ns, not significant. Error bars
represent the SEM.
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unpublished data), a greater proportion of anti-tumor CD8+
T cells expressed PD-1 in the infected lung evenwhen compared
with influenza-ovalbumin (OVA) infection-specific (OT-I) CD8+
T cells in the lungs (p < 0.01) (Figures 4A–4C). Based on this
finding and the use of PD-1 blockade in the clinical treatment
of melanoma (Hamid et al., 2013), lung cancer (Rizvi et al.,
2015), and prostate cancer (Topalian et al., 2012), we investi-
gated whether such systemic blockade in the context of influ-
enza infection would lead to recovered anti-tumor CD8+ T cell
responses in the tumor. PD-1 blockade (on days 0 and 2;
100 mg/mouse/day) decelerated tumor growth in influenza-in-
fected mice to the rate observed in untreated uninfected mice
(Figure 4D). Further, PD-1 blockade rescued the percentage of
anti-tumor CD8+ T cells within the tumor (Figures 4E and 4F).
These data demonstrate that anti-tumor CD8+ T cells shunted
to the site of infection upregulate activation and exhaustion
marker, PD-1, and that its therapeutic blockade results in
reversal of the acceleration of tumor growth by infection.
Conclusions
Overall, our findings demonstrate that acute, non-oncogenic
infection of an unrelated tissue (i.e., distal to the tumor site) re-
sults in accelerated tumor growth and hastened host death
from cancer. Based on our observations, a mechanism by
which infection impedes anti-tumor responses includes the
shunting of anti-tumor CD8+ T cell responses from the tumor
to the site of infection. The exact means by which this occurs
may involve non-specific CD8+ T cell trafficking to another (or
greater) site of inflammation (e.g., via a chemokine gradient),
where tumor-specific CD8+ T cells become hyper-activated or
exhausted (as illustrated by increased PD-1 expression at the
site of infection) and are unable to aid in the immune response
at the tumor site. Recent studies demonstrating antigen epi-
topes shared between some infections and cancers (Snyder
et al., 2014) may also explain the observed shunting of CD8+
T cells from the tumor to the infection site. Further, mechanisms
yet to be determined may be involved in driving the decision-
making process of the immune system in the context of
concomitant challenges.
Our findings define a previously unrecognized and potentially
common mechanism of immune disruption in cancer-bearing
hosts, namely acute non-oncogenic viral infection. This finding
is important because it raises concerns regarding previously un-
recognized sequelae of acute viral illness, it highlights an unex-
pected mechanism of PD-1 blockade in the treatment of cancer,
it may explain epidemiological findings describing increased
cancer prevalence and cancer-specific deaths in the context of
infection, and it contributes to our basic understanding of the im-
mune response in the context of concomitant challenges.
EXPERIMENTAL PROCEDURES
Mice and Adoptive Cell Transfers
C57BL/6 (B6; no. 00664), Balb/c (no. 00651), Braf/PTEN (no. 13590), Pmel (no.
5023), and OT-1 (no. 03831) mice, aged 6 to 8 weeks, from Jackson Labora-
tory, were housed in a specific pathogen-free facility at Rutgers Cancer Insti-
tute of New Jersey and/or Rush University Medical Center. Experiments
involving animals were carried out in accordance with respective Institutional
Animal Care and Use Committee and Institutional Biosafety Committee guide-962 Cell Reports 17, 957–965, October 18, 2016lines. Pmel (50,000) and OT-1 (50,000) cells were derived from the spleen and
adoptively transferred via injection in 100 ml PBS into the retroorbital venous
sinus.
Tumor Challenges and Monitoring
Mice (5–10 per group per experiment, as described for each experiment) were
anesthetized with isoflurane and challenged with B16-F10 (1,200–120,000
cells, as described for each experiment) via intradermal (i.d.) injection in the
right flank or 4T1-Luciferase (100,000 cells) via injection in the mammary fat
pad, as previously described (Bellavance et al., 2011; Kohlhapp et al., 2012;
Zloza et al., 2012). Before injection, these cells were cultured in RPMI 1640
plus 10% heat-inactivated fetal bovine serum (Atlanta Biologicals), 2 mM
L-glutamine (Mediatech), and 1% penicillin/streptomycin (Mediatech). Tumor
area (length 3 width) was measured using calipers. Survival of tumor-bearing
mice was defined by tumor size < 100 mm2, unless otherwise noted. For 4T1-
luciferase experiments, mice were injected with 150 mg D-Luciferin (Sigma-
Aldrich) in PBS, anesthetized with isoflurane, and imaged live with the IVIS
system (Xenogen), as per manufacturer’s instructions. For experiments
involving Braf/PTENmice, tumors were induced in somemice using 4-hydroxy
tamoxifen (4HT; 1 mg) via intravenous (i.v.) injection (Dankort et al., 2009). For
these experiments, all mice were 8 weeks old and were considered to be
melanoma-positive if one or more dermal melanomas were observed at day
60. In some experiments, tumors, spleens, and/or lungs were obtained.
Tumor Transplantation Experiments
For tumor transplantation experiments, naive B6 mice (hereafter termed
‘‘donor mice’’; Thy1.1) received an adoptive transfer of Pmel CD8+ T cells
(into the retroorbital venous sinus; 50,000 cells; Thy1.1+) on day 5 and
were challenged on day 0 with B16 melanoma (i.d. injection; 120,000 cells).
On day 12, B16 tumors (with infiltrating Thy1.1+ Pmel CD8+ T cells) were
dissected from donor B6 mice and transplanted into the flank i.d. space
(equal size) of a pair (i.e., two) of tumor-free B6 mice (‘‘recipient mice’’;
Thy1.1). On day 17, one mouse of each recipient pair was left uninfected
(control; PBS administration), and the other mouse of each recipient pair
received influenza infection (10,000 plaque-forming unit [PFUs] via intranasal
administration). On day 25, all recipient mice were euthanized and lungs
were dissected.
Infections and PD-1 Blockade
For influenza infections, mice were inoculated (10,000 PFUs in 40 ml) with influ-
enza A/H1N1/PR8 or influenza-OVA (A/H1N1/PR8-OVA) via intranasal admin-
istration (Rutigliano et al., 2014). For LCMV infections, mice were inoculated
with LCMV Armstrong strain (2 3 105 PFUs) by i.p. injection. For Staphylo-
coccus aureus (strain COL) skin infections, a 5-mm biopsy punch was used
to create four full-thickness wounds in the dorsal skin of mice, opposite from
the ventral site of the tumor (Kroin et al., 2015). Staphylococcus aureus was
applied to the wounds (1 3 107 colony-forming units [CFUs] in 10 ml PBS).
Mice were housed in individual cages after wounding to prevent cross-
contamination. For VACV skin infections, B6 mice were inoculated with
VACV (NYCBH strain) via i.d. injection (106 PFUs) and analyzed by plaque
assays (Zhang et al., 2006). For PD-1 blockade, anti-PD-1 (250 mg; clone
RMP1-14; BioXCell) or matched IgG control antibody was administered via
i.p. injection.
Flow Cytometry and Staining
Cell staining data were collected with the Canto II flow cytometer (BD) and
analyzed with FlowJo software (Tree Star) as previously described (Zloza
et al., 2012), and tissue-parenchyma (i.e., non-vascular) cells were identified
by in vivo antibody labeling of cells within the vasculature (Anderson et al.,
2014). All antibodies were purchased from eBioscience.
Statistical Analysis
Kaplan-Meier curves were used to present animal survival and tumor inci-
dence data, and log rank test was used to compare such curves. Unless other-
wise noted, Student’s t test (two-tailed) was used. All analyses were performed
using Prism software (v4.0, GraphPad). A p value < 0.05 was considered to
denote statistically significant differences.
Figure 4. PD-1 Blockade Rescues Anti-tumor Responses Impeded by Infection
(A) Experimental design for studies in which B6 mice (Thy1.1Ly5.1) received an adoptive cell transfer (ACT) on day 5 of Pmel cells (Thy1.1+Ly5.1) and OT-I
cells (Thy1.1Ly5.1+) via intravenous (i.v.) injection, were infected on day 3 with influenza-OVA, and challenged with B16 melanoma on day 0.
(B) Lungs from experiment described in (A) were resected at day 10, and PD-1 expression by Pmel and OT-I CD8+ T cells was determined by flow cytometry as
shown in representative flow plots. Axes on all plots are log scale.
(C) Cumulative bar graphs showing percentage of Pmel CD8+ T cells determined from the experiment described in (A).
(D) Experimental design (top). B6micewere infectedwith influenza (FLU) at day3 and challengedwith B16melanoma via intradermal (i.d.) injection. No adoptive
transfer of CD8+ T cells was conducted in this experiment. Some mice were treated with PD-1 blocking antibody (anti-PD-1, 100 mg) on days 0 and 2 (bottom).
(E) Tumors were resected at day 20, and endogenous melanoma-specific CD8+ T cells were identified using gp10025–33 tetramer staining after gating on
CD8+CD44+ T cells, as shown in the representative flow plots. y axis on all plots is log scale; x axis is linear scale.
(F) Cumulative bar graphs showing % of Pmel CD8+CD44+ T cells determined from the experiment described in (E).
All experiments were performed with 5–10mice per group with at least two independent repeat experiments. *p < 0.05; **p < 0.01; ***p < 0.001. ns, not significant.
Error bars represent the SEM.
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